Major Study Clears GlaxoSmithKline's Avandia of Heart Risk
Reuters -- GlaxoSmithKline's controversial diabetes drug Avandia doesn't increase overall heart risks, according to final results of a large clinical study sponsored by the world's second largest drugmaker.